ReviewCurrent cardiology reviews2025
Vericiguat: A Promising Drug for the Treatment of Heart Failure.
Review in Current cardiology reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The health and survival of people with heart failure is a growing concern due to the associated illness and death. Traditional treatments such as medication, surgery, and lifestyle changes have not significantly improved life expectancy, leading to a search for more effective drug options. A drug that can act on oxidative stress and cardiac inflammatory markers while carrying the benefits of existing therapies is needed. Targeting the soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) dependent pathway significantly reduces cardiac myocyte death and improves ejection fraction. In 2021, the USFDA approved Vericiguat, a derivative of pyrazolo [3,4-b]pyridine, to decrease the risk of cardiovascular death and hospitalization. This review provides information on the structure, pharmacokinetics, pharmacodynamics, clinical status, and treatment of Vericiguat in heart failure. Riociguat was the first sGC stimulator used in pulmonary hypertension therapy, but its short half-life required multiple dosing, making it unsuitable for cardiovascular diseases. Vericiguat was developed to address this limitation by decreasing metabolism, and both preclinical and clinical investigations have indicated its minimal pharmacokinetic interactions. This makes it appropriate for long-term use in cardiac patients with multiple comorbidities who require several medications. Vericiguat represents a promising new option for heart failure treatment, potentially improving patient outcomes and quality of life. Its compatibility with other heart failure therapies without significant drug-drug interactions further highlights its potential as a cornerstone treatment. Ongoing studies continue to explore its benefits, suggesting that vericiguat may enable more comprehensive and effective management of heart failure, reducing the burden of this debilitating condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.